InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Alkermes plc.

ALKS Clue Score59
Ireland Fiscal year ends December CIK 0001520262 Results filed 3 Nov 2026
Add to watchlist

What the insiders did Scheduled selling only

Individual transactions

33
Insider
Date
Role
Action
Shares
Price
Amount
David Joseph Gaffin
3 Nov 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,035
$46.17
$93.96K
David Joseph Gaffin
2 Oct 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$41.03
$83.46K
David Joseph Gaffin
3 Sep 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$48.01
$97.65K
Craig C. Hopkinson
1 Sep 2026
EVP R&D, Chief Medical Officer
Sold after exercise
9,000
$46.99
$422.87K
Christian Todd Nichols
17 Aug 2026
SVP, Chief Commercial Officer
Sold on a plan
664
$49.65
$32.97K
Christian Todd Nichols
17 Aug 2026
SVP, Chief Commercial Officer
Sold on a plan
6,912
$49.19
$339.97K
David Joseph Gaffin
3 Aug 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$48.58
$98.81K
Craig C. Hopkinson
3 Aug 2026
EVP R&D, Chief Medical Officer
Sold after exercise
9,000
$48.58
$437.22K
nancy lynn MD snyderman
3 Aug 2026
Director
Sold after exercise
44,472
$50.35
$2.24M
David Joseph Gaffin
6 Jul 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$54.03
$109.90K
Craig C. Hopkinson
1 Jul 2026
EVP R&D, Chief Medical Officer
Sold after exercise
700
$52.13
$36.49K
Craig C. Hopkinson
1 Jul 2026
EVP R&D, Chief Medical Officer
Sold after exercise
8,300
$51.46
$427.13K
Christopher I Wright
12 Jun 2026
Director
Sold on a plan
2,000
$45.10
$90.20K
David Joseph Gaffin
4 Jun 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$43.05
$87.56K
Craig C. Hopkinson
1 Jun 2026
EVP R&D, Chief Medical Officer
Sold after exercise
9,000
$41.67
$375.04K
Samuel Joseph Parisi
29 May 2026
VP, Finance (Interim PAO)
Sold after exercise
16,217
$42.36
$687.01K
David Joseph Gaffin
4 May 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$33.20
$67.53K
Craig C. Hopkinson
1 May 2026
EVP R&D, Chief Medical Officer
Sold after exercise
9,000
$33.40
$300.56K
David Joseph Gaffin
6 Apr 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$34.57
$70.32K
Craig C. Hopkinson
1 Apr 2026
EVP R&D, Chief Medical Officer
Sold after exercise
9,000
$35.51
$319.60K
David Joseph Gaffin
3 Mar 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$29.76
$60.53K
David Joseph Gaffin
2 Mar 2026
EVP, CLO, Alkermes, Inc.
Sold on a plan
2,034
$29.29
$59.58K
Craig C. Hopkinson
2 Mar 2026
EVP R&D, Chief Medical Officer
Sold after exercise
9,000
$29.72
$267.49K
Christian Todd Nichols
2 Mar 2026
SVP, Chief Commercial Officer
Sold on a plan
6,000
$30.00
$180.00K
Samuel Joseph Parisi
2 Mar 2026
VP, Finance (Interim PAO)
Sold on a plan
6,890
$29.29
$201.81K
Shane Cooke
2 Feb 2026
Director
Sold after exercise
32,113
$34.78
$1.12M
Shane Cooke
2 Feb 2026
Director
Sold after exercise
29,087
$34.34
$998.80K
Craig C. Hopkinson
2 Feb 2026
EVP R&D, Chief Medical Officer
Sold after exercise
4,000
$33.54
$134.16K
Craig C. Hopkinson
2 Feb 2026
EVP R&D, Chief Medical Officer
Sold after exercise
5,000
$34.24
$171.22K
Craig C. Hopkinson
8 Jan 2026
EVP R&D, Chief Medical Officer
Sold after exercise
5,000
$30.00
$150.01K
Craig C. Hopkinson
2 Jan 2026
EVP R&D, Chief Medical Officer
Sold on a plan
4,000
$28.00
$112.00K
Craig C. Hopkinson
3 Dec 2025
EVP R&D, Chief Medical Officer
Sold after exercise
3,748
$30.00
$112.45K
Craig C. Hopkinson
1 Dec 2025
EVP R&D, Chief Medical Officer
Sold on a plan
4,000
$29.30
$117.20K

What was left out

Form 4 filings counted 63
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 17
Sales straight out of an exercise 16
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 776,396
History held since 20 Sep 2011